Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Haemophilus Influenzae Type b Infections-Pipeline Review, H1 2015

Haemophilus Influenzae Type b Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Haemophilus Influenzae Type b Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Haemophilus Influenzae Type b Infections-Pipeline Review, H1 2015', provides an overview of the Haemophilus Influenzae Type b Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Haemophilus Influenzae Type b Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Haemophilus Influenzae Type b Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Haemophilus Influenzae Type b Infections Overview 8

Therapeutics Development 9

Pipeline Products for Haemophilus Influenzae Type b Infections-Overview 9

Pipeline Products for Haemophilus Influenzae Type b Infections-Comparative Analysis 10

Haemophilus Influenzae Type b Infections-Therapeutics under Development by Companies 11

Haemophilus Influenzae Type b Infections-Therapeutics under Investigation by Universities/Institutes 13

Haemophilus Influenzae Type b Infections-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Haemophilus Influenzae Type b Infections-Products under Development by Companies 18

Haemophilus Influenzae Type b Infections-Products under Investigation by Universities/Institutes 20

Haemophilus Influenzae Type b Infections-Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co., Ltd 21

Biological E. Limited 22

Chongqing Zhifei Biological Products Co., Ltd. 23

Indian Immunologicals Limited 24

LG Life Sciences, Ltd. 25

Novartis AG 26

Nuron Biotech, Inc. 27

Panacea Biotec Limited 28

Sanofi Pasteur SA 29

Sinovac Biotech Ltd. 30

Zydus Cadila Healthcare Limited 31

Haemophilus Influenzae Type b Infections-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Combination Products 33

Assessment by Target 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

haemophilus influenza [serotype B] vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

haemophilus influenzae [serotype B] + meningococcal polysaccharide [serotypes A, C, Y, W-135] vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

haemophilus influenzae [serotype B] vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

haemophilus influenzae [serotype B] vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

haemophilus influenzae [serotype B] vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

haemophilus influenzae type b vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

haemophilus influenzae vaccine [type B]-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

NU-300-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

PR-5I-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Haemophilus Influenzae Type b Infections-Recent Pipeline Updates 59

Haemophilus Influenzae Type b Infections-Dormant Projects 60

Haemophilus Influenzae Type b Infections-Product Development Milestones 61

Featured News & Press Releases 61

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 61

Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

Number of Products under Development for Haemophilus Influenzae Type b Infections, H1 2015 9

Number of Products under Development for Haemophilus Influenzae Type b Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Haemophilus Influenzae Type b Infections-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 21

Haemophilus Influenzae Type b Infections-Pipeline by Biological E. Limited, H1 2015 22

Haemophilus Influenzae Type b Infections-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 23

Haemophilus Influenzae Type b Infections-Pipeline by Indian Immunologicals Limited, H1 2015 24

Haemophilus Influenzae Type b Infections-Pipeline by LG Life Sciences, Ltd., H1 2015 25

Haemophilus Influenzae Type b Infections-Pipeline by Novartis AG, H1 2015 26

Haemophilus Influenzae Type b Infections-Pipeline by Nuron Biotech, Inc., H1 2015 27

Haemophilus Influenzae Type b Infections-Pipeline by Panacea Biotec Limited, H1 2015 28

Haemophilus Influenzae Type b Infections-Pipeline by Sanofi Pasteur SA, H1 2015 29

Haemophilus Influenzae Type b Infections-Pipeline by Sinovac Biotech Ltd., H1 2015 30

Haemophilus Influenzae Type b Infections-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Assessment by Combination Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Haemophilus Influenzae Type b Infections Therapeutics-Recent Pipeline Updates, H1 2015 59

Haemophilus Influenzae Type b Infections-Dormant Projects, H1 2015 60

List of Figures

Number of Products under Development for Haemophilus Influenzae Type b Infections, H1 2015 9

Number of Products under Development for Haemophilus Influenzae Type b Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 32

Assessment by Combination Products, H1 2015 33

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Beijing Minhai Biotechnology Co., Ltd

Biological E. Limited

Chongqing Zhifei Biological Products Co., Ltd.

Indian Immunologicals Limited

LG Life Sciences, Ltd.

Novartis AG

Nuron Biotech, Inc.

Panacea Biotec Limited

Sanofi Pasteur SA

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Haemophilus Influenzae Type b Infections Therapeutic Products under Development, Key Players in Haemophilus Influenzae Type b Infections Therapeutics, Haemophilus Influenzae Type b Infections Pipeline Overview, Haemophilus Influenzae Type b Infections Pipeline, Haemophilus Influenzae Type b Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com